FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979329996> ?p ?o ?g. }

• W2979329996 abstract "Abstract Abstract 1264 Background: Recombinant activated coagulation factor VII (rFVIIa) has been increasingly used in non-hemophiliac patients for unapproved indications. We undertook a 10 year nation-wide retrospective survey in order to evaluate the use of rFVIIa in Iceland in patients with intractable extra-cranial hemorrhage. Material and methods: Hospital charts of all patients that received rFVIIa between 1999–2008 at Landspitali, the single institution administering rFVIIa in Iceland, were reviewed and indications, coagulation profiles and clinical outcome were evaluated. This analysis focuses on patients treated off-label for desperate (intractable) extra-cranial hemorrhage (IH), ie only patients in who all other measures were considered to have failed to stop hemorrhage. Results: rFVIIa was used for IH in 55 patients (median age 53 yrs, range; 0–84, 51% males). This included IH in open heart surgery (n=23), non-cardiac surgery (n=7), post-partum hemorrhage (n=9), multitrauma (n=8) and miscellaneous (n=8). A single rFVIIa dose was used in 86% of cases and hemorrhage was considered effectively contained by immediate clinical response to rFVIIa in 81% of the IH cases. Survival at 30 days for all patients was 68%. Out of 55 patients with IH, six died within 24 hours of administration of rFVIIa (five assessed clinically as rFVIIa non-responders) and 11 other patients (total 17 patients, 31%) died within 30 days (six non-responders). The 24-hour mortality in rFVIIa clinical responders and non-responders was 2% and 50% respectively (p=0.0004) and the 30 day mortality was 25% and 60% respectively (p=0.05). The need for transfusion of blood products was significantly decreased (p<0.01) and also the prothrombin time (20.0 to 13.3 sec, p<0.0001). Conclusion: The majority of unselected consecutive patients receiving rFVIIa as last resort treatment for IH were considered to have favorable immediate clinical response as well as reduced transfusion requirements and normalisation of coagulation parameters. Also, patients deemed with clinical response to rFVIIa may have had lower mortality. Disclosures: Off Label Use: Activated recombinant factor VII for use in desperately bleeding patients." @default.
• W2979329996 created "2019-10-18" @default.
• W2979329996 creator A5003429558 @default.
• W2979329996 creator A5005255396 @default.
• W2979329996 creator A5023759953 @default.
• W2979329996 creator A5034972381 @default.
• W2979329996 date "2011-11-18" @default.
• W2979329996 modified "2023-09-28" @default.
• W2979329996 title "Activated Recombinant Factor VIIa for Intractable Extra-Cranial Hemorrhage in 55 Consecutive Patients" @default.
• W2979329996 doi "https://doi.org/10.1182/blood.v118.21.1264.1264" @default.
• W2979329996 hasPublicationYear "2011" @default.
• W2979329996 type Work @default.
• W2979329996 sameAs 2979329996 @default.
• W2979329996 citedByCount "0" @default.
• W2979329996 crossrefType "journal-article" @default.
• W2979329996 hasAuthorship W2979329996A5003429558 @default.
• W2979329996 hasAuthorship W2979329996A5005255396 @default.
• W2979329996 hasAuthorship W2979329996A5023759953 @default.
• W2979329996 hasAuthorship W2979329996A5034972381 @default.
• W2979329996 hasConcept C126322002 @default.
• W2979329996 hasConcept C141071460 @default.
• W2979329996 hasConcept C186738567 @default.
• W2979329996 hasConcept C2778382381 @default.
• W2979329996 hasConcept C2778961111 @default.
• W2979329996 hasConcept C2780930249 @default.
• W2979329996 hasConcept C2908626413 @default.
• W2979329996 hasConcept C42219234 @default.
• W2979329996 hasConcept C71924100 @default.
• W2979329996 hasConceptScore W2979329996C126322002 @default.
• W2979329996 hasConceptScore W2979329996C141071460 @default.
• W2979329996 hasConceptScore W2979329996C186738567 @default.
• W2979329996 hasConceptScore W2979329996C2778382381 @default.
• W2979329996 hasConceptScore W2979329996C2778961111 @default.
• W2979329996 hasConceptScore W2979329996C2780930249 @default.
• W2979329996 hasConceptScore W2979329996C2908626413 @default.
• W2979329996 hasConceptScore W2979329996C42219234 @default.
• W2979329996 hasConceptScore W2979329996C71924100 @default.
• W2979329996 hasLocation W29793299961 @default.
• W2979329996 hasOpenAccess W2979329996 @default.
• W2979329996 hasPrimaryLocation W29793299961 @default.
• W2979329996 hasRelatedWork W1910108907 @default.
• W2979329996 hasRelatedWork W2010030390 @default.
• W2979329996 hasRelatedWork W2026851381 @default.
• W2979329996 hasRelatedWork W2032158235 @default.
• W2979329996 hasRelatedWork W2078746591 @default.
• W2979329996 hasRelatedWork W2091050810 @default.
• W2979329996 hasRelatedWork W2094457286 @default.
• W2979329996 hasRelatedWork W2323516193 @default.
• W2979329996 hasRelatedWork W2326668685 @default.
• W2979329996 hasRelatedWork W2415294823 @default.
• W2979329996 hasRelatedWork W2415619080 @default.
• W2979329996 hasRelatedWork W2417631441 @default.
• W2979329996 hasRelatedWork W2547578669 @default.
• W2979329996 hasRelatedWork W2550102555 @default.
• W2979329996 hasRelatedWork W2553675905 @default.
• W2979329996 hasRelatedWork W2557564140 @default.
• W2979329996 hasRelatedWork W2595345555 @default.
• W2979329996 hasRelatedWork W2741968472 @default.
• W2979329996 hasRelatedWork W2913414323 @default.
• W2979329996 hasRelatedWork W2978485330 @default.
• W2979329996 isParatext "false" @default.
• W2979329996 isRetracted "false" @default.
• W2979329996 magId "2979329996" @default.
• W2979329996 workType "article" @default.